- Home
- RCUS vs NEA Comparison
RCUS vs NEA Comparison
Compare RCUS & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | NEA |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | RCUS | NEA |
|---|---|---|
| Price | $23.65 | $11.48 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $31.90 | N/A |
| AVG Volume (30 Days) | 798.2K | ★ 864.4K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $247,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.92 | $10.60 |
| 52 Week High | $28.72 | $11.90 |
Technical Indicators
Market Signals| Indicator | RCUS | NEA |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 53.14 |
| Support Level | $22.61 | $11.46 |
| Resistance Level | $24.33 | $11.68 |
| Average True Range (ATR) | 1.05 | 0.09 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 34.06 | 69.05 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.